OLX75016 (OLX702A)
Phase 1A MASH and obesity candidate licensed to Eli Lilly in February 2025 in a deal worth up to $630 million; OliX runs the Phase 1 trial in Australia.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Runs Phase 1 for a candidate licensed to Lilly and an Australian trial of its own hair-loss candidate while doing joint research with L'Oréal. Also seen: Global approvals · expansion
Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing
A drug developer using RNA interference (siRNA) to build treatments for metabolic, skin and hair conditions.
A MASH and obesity candidate licensed to Eli Lilly in February 2025 in a deal worth up to $630 million; OliX runs the Phase 1 trial in Australia.
A male-pattern hair-loss candidate that lowers androgen receptor expression; dosing of all patients in its Australian Phase 1b trial is complete.
Its in-house siRNA platform, used for the hair-loss candidate OLX104C and other programs.
Signed a joint research agreement with L'Oréal on siRNA-based skin and hair science.
Dosed the first patient in the Australian Phase 1b/2a trial of OLX104C.
Completed dosing of all patients in the Australian Phase 1b trial of OLX104C.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.